| Followers | 141 |
| Posts | 5785 |
| Boards Moderated | 0 |
| Alias Born | 06/09/2020 |
Thursday, November 23, 2023 4:11:03 PM
First your own comment Lykiri regarding these ....
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=171641646
And then Al Musella debunking
I completely disagree with the paper. Luckily it was just submitted and not peer reviewed. It would never pass peer review. The easiest fact to show they are wrong is they emphasis "post-hoc" a few times. Had they read the paper, they would have seen ,,,
— Al Musella (@AlMusella) December 23, 2022
I agree completely. Did you know the novocure trials got picked apart even worse than the dcvax trials? I am a big proponent of Optune and fought against the negativity when the vast majority of clinicians were against it. There are still a few against, even after 250+ papers
— Al Musella (@AlMusella) December 23, 2022
"This is the first SAP that has been submitted for the Trial, and it is being submitted prior to Data Lock
— Al Musella (@AlMusella) December 23, 2022
and unblinding of the study results." The definition of "Post-Hoc" is "After the event" - which implies they saw the data before creating the SAP, and they didn't.
The authors want the study repeated with no crossover. I wonder if they would allow their kids or parents to participate in such a trial, with the risk of a placebo. If they wouldn't allow their family to do it, why should we.
— Al Musella (@AlMusella) December 23, 2022
Bottom Line: This study has flaws, as do ALL phase 3 trials. They are not bad enough to disregard the conclusion that DCVAX helps patients. We need to get this approved ASAP, then we will be able to experiment with combinations that will improve these already impressive results
— Al Musella (@AlMusella) December 23, 2022
I have been to many FDA meetings both public and private. I testified at the advisory committee meetings for avastin, optune and gleolan. The trials for each of these were picked apart worse than we are seeing here for dcvax. They all were approved
— Al Musella (@AlMusella) December 24, 2022
Recent NWBO News
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • InvestorsHub NewsWire • 05/11/2026 01:00:00 PM
- CNS Drug Delivery Breakthroughs Unlock Significant Biotech Market Opportunities • GlobeNewswire Inc. • 05/11/2026 12:30:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:38:00 PM
- Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform • PR Newswire (US) • 04/30/2026 04:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM

